The historical rank and industry rank for ProQR Therapeutics NV's Days Payable or its related term are showing as below:
MEX:PRQRN's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 113.56 * Ranked among companies with meaningful Days Payable only.
ProQR Therapeutics NV's Days Payable
stayed the same
from Mar. 2025 (0.00) to Mar. 2026 (0.00).
stayed the same
ProQR Therapeutics NV Days Payable Related Terms
ProQR Therapeutics NV Days Payable Historical Data
* Premium members only.
The historical data trend for ProQR Therapeutics NV's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:PRQRN vs GALT, HRTX, PLYX: Days Payable Comparison
For the Biotechnology subindustry, ProQR Therapeutics NV's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ProQR Therapeutics NV Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ProQR Therapeutics NV's Days Payable distribution charts can be found below:
* The bar in red indicates where ProQR Therapeutics NV's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
ProQR Therapeutics NV's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ProQR Therapeutics NV (MEX:PRQRN) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on ProQR Therapeutics NV and its competitors. According to the industry distribution chart, ProQR Therapeutics NV ranks #999999 out of 708 companies in the Biotechnology industry.
Is ProQR Therapeutics NV's Days Payable too high?
ProQR Therapeutics NV's current Days Payable is 0.00. Based on the distribution chart, ProQR Therapeutics NV ranks #999999 out of 708 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ProQR Therapeutics NV has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does ProQR Therapeutics NV's Days Payable compare to GALT and HRTX?
According to the Biotechnology industry distribution chart, ProQR Therapeutics NV ranks #999999 out of 708 companies for Days Payable. This places ProQR Therapeutics NV in the lower half of its industry. The industry median Days Payable is 113.56. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 708 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on ProQR Therapeutics NV and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ProQR Therapeutics NV's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProQR Therapeutics NV stock overvalued right now?
ProQR Therapeutics NV (MEX:PRQRN) has a current Days Payable of 0.00. The stock's GF Value™ is MXN40.07, compared to a current price of MXN36.00 — trading 10.2% below its estimated fair value. The current Days Payable is 0.00. ProQR Therapeutics NV's overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For ProQR Therapeutics NV (MEX:PRQRN), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ProQR Therapeutics NV (MEX:PRQRN) Overvalued in 2026?
Based on GuruFocus' analysis, ProQR Therapeutics NV stock appears to be undervalued.
The current stock price of MXN36.00 is trading 10.2% below its estimated GF Value™ of MXN40.07.
Key valuation signals for MEX:PRQRN:
Days Payable: 0.00
GF Value™: MXN40.07 vs. price of MXN36.00 (10.2% below fair value)
No single metric tells the full story. See the MEX:PRQRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.
44GF Score
Get the complete analysis for MEX:PRQRN
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:PRQRN has been successfully added to your 
